Patents by Inventor Hiroyuki Higashiyama

Hiroyuki Higashiyama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Epilepsy treatment agent
    Patent number: 11660275
    Abstract: Provided is a combination agent that combines N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide with an AMPA-type glutamate receptor antagonist such as 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one or 2-fluoro-6-(3-fluoro-8-oxo-7-(pyridin-3-yl)-7,8-dihydro-6H-pyrano[3,2-b:5,4-b?]dipyridin-9-yl)benzonitrile, and it has potential for use as a therapeutic agent for epilepsy.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: May 30, 2023
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Hiroyuki Higashiyama, Hisashi Wakita, Yoshimasa Ito, Yoshihide Osada
  • EPILEPSY TREATMENT AGENT
    Publication number: 20210000771
    Abstract: Provided is a combination agent that combines N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide with an AMPA-type glutamate receptor antagonist such as 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one or 2-fluoro-6-(3-fluoro-8-oxo-7-(pyridin-3-yl)-7,8-dihydro-6H-pyrano[3,2-b:5,4-b?]dipyridin-9-yl)benzonitrile, and it has potential for use as a therapeutic agent for epilepsy.
    Type: Application
    Filed: March 18, 2019
    Publication date: January 7, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Hiroyuki Higashiyama, Hisashi Wakita, Yoshimasa Ito, Yoshihide OSADA
  • Therapeutic and/or preventive agent comprising 1-indansulfamide derivative for pain
    Patent number: 9610262
    Abstract: The present invention is directed to a method of treating pain comprising the administering the following 1-indansulfamide compounds: N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, (?)-N-(7-chloro-2,2,5-trifluoro-2,3-dihydro-1H-inden-1-yl)sulfamide, N-[(1S)-2,2-difluoro-7-methyl-2,3-dihydro-1H-inden-1-yl]sulfamide, and N-[(1S)-2,2,5-trifluoro-7-methyl-2,3-dihydro-1H-inden-1-yl]sulfamide.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: April 4, 2017
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Hiroyuki Higashiyama, Yuji Kazuta, Keisuke Hashimoto
  • THERAPEUTIC AND/OR PREVENTIVE AGENT COMPRISING 1-INDANSULFAMIDE DERIVATIVE FOR PAIN
    Publication number: 20160303058
    Abstract: A medicine comprising a 1-indansulfamides compound such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, or N-[(1S)-2,2-difluoro-7-methyl-2,3-dihydro-1H-indene-1-yl]sulfamide or a pharmaceutically acceptable salt thereof, has an analgesic effects in the mouse hot-plate test and rat constriction nerve injury model and thus holds promise as a therapeutic agent for acute and chronic pain.
    Type: Application
    Filed: December 17, 2014
    Publication date: October 20, 2016
    Inventors: Hiroyuki Higashiyama, Yuji Kazuta, Keisuke Hashimoto
  • Indanesulfamide derivatives
    Patent number: 9018260
    Abstract: Novel indansulfamide derivatives or a pharmaceutically acceptable salt thereof such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, N-[(1S)-2,2,4,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, (+)-N-(2,2,4,6,7-pentafluoro-2,3-dihydro-1H-inden-1-yl)sulfamide, have an action of improving Seizure Severity Index (Score) in mice kindling model. Thus the compounds or the salt thereof are expected as a drug for treating epilepsy.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: April 28, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yuji Kazuta, Toru Watanabe, Keiichi Sorimachi, Minako Saito, Yoichi Kita, Toshiaki Tanaka, Hiroyuki Higashiyama, Takahisa Hanada, Tetsuyuki Teramoto, Takashi Kosasa, Yukio Ishikawa
  • NOVEL INDANESULFAMlDE DERIVATIVES
    Publication number: 20140371319
    Abstract: Novel indansulfamide derivatives or a pharmaceutically acceptable salt thereof such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, N-[(1S)-2,2,4,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, (+)-N-(2,2,4,6,7-pentafluoro-2,3-dihydro-1H-inden-1-yl)sulfamide, have an action of improving Seizure Severity Index (Score) in mice kindling model. Thus the compounds or the salt thereof are expected as a drug for treating epilepsy.
    Type: Application
    Filed: June 17, 2013
    Publication date: December 18, 2014
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yuji Kazuta, Toru Watanabe, Keiichi Sorimachi, Minako Saito, Yoichi Kita, Toshiaki Tanaka, Hiroyuki Higashiyama, Takahisa Hanada, Tetsuyuki Teramoto, Takashi Kosasa, Yukio Ishikawa